# Aciclovir (CRE) — Azathioprin (FTA, TAB) — Bisoprolol + HCT (FTA) — Carbidopa + Levodopa (RET) — Carbidopa + Levodopa (TAB) — Carglumsäure (TSE) — Cinnarizin + Dimenhydrinat (TAB) — Clotrimazol (CRE) — Diltiazem HCl (REK, RET) — Doxepin (FTA) — Enalapril (TAB) — Enalapril + HCT (TAB) — Felodipin (RET) — Fluticason 17-propionat + Azelastin (NAS) — Glimepirid (TAB) — Hydrochlorothiazid (TAB) — Hydro

Abschluss eines Generikarabattvertrags für den o.  g.  Wirkstoff.

Source: QUOTA CÔTE — https://quotacote.com/opportunites/aciclovir-cre-azathioprin-fta-tab-bisoprolol-hct-fta-carbidopa-levodop--0662e844-ef2c-4b0d-999c-914cd2bb161f
Last checked by QUOTA: 2026-10-16
Methodology: https://quotacote.com/a-propos-des-donnees

## Key facts

- Country: Allemagne [FACT]
- Deadline: 2026-11-25 [FACT]
- Last checked by QUOTA: 2026-10-16 [FACT]
- Sector (QUOTA normalisation): Autre [ANALYSIS]
- Summary: QUOTA editorial summary of the source notice [ANALYSIS]

## Entities

- geography: Allemagne
- funder: GWQ ServicePlus AG
- buyer: GWQ ServicePlus AG

## Limitations

- QUOTA republishes a normalised summary, not the tender documents themselves.
- Commercial details (source dossier, full deadline history, budget) are reserved for subscribers.